Clinical Trials Browser

Unknown × Bronchiolitis Obliterans Syndrome × ponatinib × Clear all

NCT04043676 2019-08-02

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive